Navigation Links
Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer
Date:4/4/2011

ceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.

P-LLY

This press release contains forward-looking statements about the potential of LY2784544 and LY2940680 and reflects Lilly's current beliefs. However, as with any pharmaceutical compound, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that either compound will be approved by the relevant regulatory authorities or prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

(1) Brandes AA, Ermani M, Amista P, et al.: The treatment of adults with medulloblastoma: a prospective study. Int J Radiat Oncol Biol Phys 57 (3): 755-61, 2003.

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... it expects revenues for the fourth quarter of 2013 ... revenues to approximately $208 million. "Our full-year ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... OAKS, Calif., April 13, 2011 Amgen (NASDAQ: ... first quarter financial results on Wednesday, April 20, 2011 after ... be followed by a conference call with the investment community ... Amgen will be Kevin Sharer, chairman and chief executive officer, ...
... 13, 2011 Perrigo (Nasdaq: PRGO;TASE) today announced that ... TEVA ), has received final OTC approval to sell ... tablets; the generic equivalents of Sanofi-Aventis, Allegra 60 mg ... for these products, and Teva and Sanofi-Aventis have settled ...
Cached Medicine Technology:Amgen Announces Webcast of 2011 First Quarter Financial Results 2Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets 2Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets 3
(Date:7/9/2014)... A retrospective study conducted by researchers at Tufts University ... adults with intellectual and developmental disabilities, the likelihood of ... dental care increased. The findings, published in the July/August ... help improve interventions designed to address the oral health ... reviewed the dental records of 107 patients at one ...
(Date:7/9/2014)... , , , , , ... , , , , ... the microphone is 50m downrange from the firer and approximately 30cm from the bullet... , , ... , , , , , ... , , , , , , University ...
(Date:7/9/2014)... of Medicine of the University of Southern California ... component of the immune system are completely resistant ... The discovery suggests that blocking this immune system ... and hyper-inflammatory diseases such as rheumatoid arthritis and ... online on June 23 in The Journal ...
(Date:7/8/2014)... The Department of Defense,s Defense Advanced Research Projects ... up to $2.5 million to develop an implantable ... stimulate neurons within the brain to help restore ... research builds on the understanding that memory is ... of the brain encode information, store it and ...
(Date:7/8/2014)... In a study published yesterday in the scientific ... Jolla Institute (LJI) led by Pandurangan Vijayanand, Ph.D. identify new ... affects over 200 million people world wide. , An ... divided into small sections or ,neighborhoods., Scientists can determine ... for gene production, by looking for a marker on the ...
Breaking Medicine News(10 mins):Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3Health News:LJI develops new approach to identify genes poised to respond in asthma patients 2
... TORRANCE, Calif., April 27 According to new ... , supplements of Lactobacillus casei strain Shirota may ... fatigue syndrome (CFS). Thirty-nine patients with CFS ... Shirota or placebo for two months. Compared ...
... Services Department declares a Public Health EmergencyHARRISBURG, Pa., April ... working with federal officials to contain the impact of ... in the declaration of a national public health emergency ... to educate the public and health care providers of ...
... toxins in the products we use for lifestyle convenience, ... toxic load on our bodies contributing to chronic illnesses, ... awareness of our environmental exposures, Metametrix Clinical Laboratory ( ... release of three new testing profiles in the Toxic ...
... 100 Exhibits, Forums on Health Care and Financial Security, ... Top Musicians***LOS LOBOS TO HEADLINE ENTERTAINMENT***SAN ANTONIO, April 27 ... for people age 50+, today announced it will bring ... San Antonio on May 15-16. The two-day, cross-generational ...
... screen at 40, but yearly PSA may not be necessary, ... guidelines on prostate cancer screening suggest that annual PSA blood ... same guidelines call for a "baseline" PSA test at the ... (PSA) test to detect early signs of prostate cancer should ...
... WHAT: , Media may now register to attend ... Symposium of the Cardiovascular Research Foundation. TCT gathers ... world to present and discuss the latest developments ... medicine. Now in its 21st year, TCT brings ...
Cached Medicine News:Health News:New Study Shows Supplementing With Probiotics May Ease Anxiety 2Health News:Pennsylvania Working Closely With Federal Partners to Contain Impact of Swine Flu 2Health News:Pennsylvania Working Closely With Federal Partners to Contain Impact of Swine Flu 3Health News:Metametrix Announces New Toxic Effects Profiles to Help Combat Growing Concerns About Toxicity and Health 2Health News:AARP to Host Cross-Generational 'Life Festival' in San Antonio May 15-16 2Health News:AARP to Host Cross-Generational 'Life Festival' in San Antonio May 15-16 3Health News:Experts Back Away From Annual PSA Test 2Health News:Experts Back Away From Annual PSA Test 3Health News:Media registration now open for TCT 2009 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: